Targeting B Cells for Antibody-Mediated Graft Rejection

by | Oct 22, 2019 | Edelson, Brian, Fremont, Daved, Liu, Chang, Nelson, Christopher, Wang, Xiaoli

— Disease Indications

Drug type: Biologic – engineered protein

Drug class: First in class

Technology:

A recombinant fusion protein that depletes B cells in the recipient that are specific to the donor HLA. The fusion protein offers a targeted therapy for antibody-mediated rejection in the …